

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Drug Program®

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|-------------------------------|----------------------------|---------------------------|----------------|-------------|-------------------|
| baclofen sus 25mg/5ml (Brand: Fleqsuvy®) | G + PA + QL (16ml per day) | No Change (New Generic) | | No Change | No Change | 07/03/23 |
| vancomycin sol 25mg/ml (Brand: Firvanq®) | G + AL (Max Age 12) | No Change (New Generic) | | No Change | No Change | 07/31/23 |
| indomethacin sup 50mg (Brand: Indocin®) | G | No Change (New Generic) | | No Change | No Change | 08/07/23 |
| saxagliptin tab 2.5mg, 5mg (Brand: Onglyza™) | G | No Change (New Generic) | | No Change | No Change | 08/07/23 |
| saxa/metfor tab 2.5-1000mg, 5-1000mg, 5-500mg (Brand: Kombiglyze™ XR) | G | No Change (New Generic) | | No Change | No Change | 08/14/23 |
| tiotrop brom cap 18mcg (Brand: Spiriva® HandiHaler®) | NPD + PA | No Change (New Generic) | Spiriva® | No Change | No Change | 08/21/23 |
| joyeaux tab 0.1-20 (Brand: Balcoltra®) | G | No Change (New Generic) | | No Change | No Change | 08/28/23 |
| lisdexamfetamine chw (Brand: Vyvanse® Chew) | G + QL (1 tab per day) | No Change (New Generic) | | No Change | No Change | 09/04/23 |
| lisdexamfetamine cap (Brand: Vyvanse® Cap) | G + QL (1 cap per day) | No Change (New Generic) | | No Change | No Change | 09/04/23 |
| tretinoin gel 0.08% (Brand: Retin-A Micro® Gel) | G + AL (Max Age 25) | No Change (New Generic) | | No Change | No Change | 09/04/23 |
| brimonidine sol 0.1% (Brand: Alphagan® P) | G | No Change (New Generic) | | No Change | No Change | 09/11/23 |

* = for Specialty plans

** = May be available as generic for certain plans

(continued)

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(4/24 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|-----------------------------------|---------------------------------------|--|-------------|-------------|----------------|
| bexagliflozn tab 20mg (Brand: Brenzavvy®) | NPD + PA | No Change (New Authorized Generic) | | No Change | No Change | 11/06/23 |
| Talzenna® Cap 0.1MG, 0.35MG | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/03/23 |
| Yuflyma® 2syr Kit 40/0.4ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 08/07/23 |
| Suflave™ Sol | NPD + PA + QL (4 per 365 days) | No Change (New Drug) | Suprep® or Clenpiq® | No Change | No Change | 07/10/23 |
| Austedo® XR Tab Titr Kit | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/17/23 |
| Brenzavvy™ Tab 20mg | NPD + PA | No Change (New Drug) | One of the following: Jardiance®, Synjardy® [XR], Glyxambi® or Trijardy® XR AND One of the following: Farxiga® or Xigduo® XR | No Change | No Change | 07/24/23 |
| Vanflyta® Tab 17.7mg, 26.5mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 07/31/23 |
| Cosentyx® Inj 300/2ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 08/07/23 |
| Ngenla™ Inj 24/1.2ml, 60/1.2ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 08/07/23 |
| Opvee® Spray 2.7/0.1 | NPD + QL (6 units per 30 days) | No Change (New Drug) | | No Change | No Change | 08/21/23 |
| Airsupra™ AER 90-80mcg | NPD + PA | No Change (New Drug) | Both of the following: one inhaled corticosteroid (ICS) with albuterol AND minimum 30-day supply of brand Symbicort® | No Change | No Change | 08/28/23 |

*= for Specialty plans

** = May be available as generic for certain plans

(continued)

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(4/24 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|---|-------------------------|-------------------------|---|-------------|-------------|----------------|
| nitrofurantoin susp 50mg/5ml | G + AL (Max Age 12) | No Change (New Drug) | | No Change | No Change | 09/04/23 |
| Breo™ Ellipta® Inh 50-25mcg | PB | No Change (New Drug) | | No Change | No Change | 09/04/23 |
| Ojjaara™ | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/25/23 |
| Abrilada™ Inj 20/0.4ml, 40/0.8ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 10/30/23 |
| Lodoco® | NPD + PA | No Change (New Drug) | | No Change | No Change | 09/11/23 |
| Zepbound™ Inj | NPD + PA | No Change (New Drug) | | No Change | No Change | 11/06/23 |
| Breyna™ Aer 80/4.5, 160/4.5 | NPD + PA | No Change | TWO of the following: Breo™ Ellipta®, Symbicort® or Advair® HFA | No Change | No Change | 07/31/23 |
| vancomycin sol 50mg/ml | G + AL (Max Age 12) | No Change | | No Change | No Change | 08/14/23 |
| Iyuzeh™ Dro 0.005% | NPD + PA | No Change | ONE of the following generics: latanoprost, bimatoprost, travoprost AND Lumigan® | No Change | No Change | 08/21/23 |
| Jesduvroq® | NPD + PA | No Change | | No Change | No Change | 09/18/23 |
| Sohonos™ | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/04/23 |
| Akeega™ | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/18/23 |
| Adalimumab® Kit 40/0.8ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/25/23 |
| Adalimumab®-Adbm Psoriasis/Uveitis Starter | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/25/23 |

*= for Specialty plans

** = May be available as generic for certain plans

(continued)

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(4/24 version)

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|-------------------------|---|---|--------------|-------------|----------------|
| Adalimumab® Kit 10/0.2ml, 20/0.4ml, 40/0.8ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/25/23 |
| Adalimumab®-Adbm Crohns/Uc/Hs Starter | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 09/25/23 |
| Xdemvy® Dro 0.25% | NPD + PA | NPD | | No Change | PA Removal | 04/01/24 |
| Zurzuvaе™ Cap 20mg, 25mg | NPD | NPD + QL (2 caps per day; D/S 14 days per 365 days) | | No Change | QL Addition | 04/01/24 |
| Zurzuvaе™ Cap 30mg | NPD | NPD + QL (1 cap per day; D/S 14 days per 365 days) | | No Change | QL Addition | 04/01/24 |
| Flovent® HFA Aerosol 44mcg/ACT, 110mcg/ACT, 220mcg/ACT Inhalation | PB | NPD + PA* (Bypass PA for members 5 years of age and under) | Both of the following: Arnuity® Ellipta® and Pulmicort Flexhaler™ | Brand Uptier | PA Addition | 01/01/24 |
| Fluticasone propionate HFA aerosol 44mcg/ACT, 110mcg/ACT, 220mcg/ACT Inhalation | NPD + PA | NPD + PA* (Bypass PA for members 5 years of age and under) | Both of the following: Arnuity® Ellipta® and Pulmicort Flexhaler™ | No Change | No Change | 01/01/24 |

*= for Specialty plans

** = May be available as generic for certain plans

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

(4/24 version)

Abbreviation Key

| | |
|---|--|
| G | Generic |
| LCG | Low Cost Generic. Benefit may vary; not all plans provide this incentive. |
| ACA | Affordable Care Act preventative drugs |
| PB | Preferred Brand |
| NPD | Non-Preferred Drug |
| SP | Specialty Drug. Specialty Tier cost-share will apply for those benefits that have a prescription drug specialty tier. |
| PA | Prior Authorization is required. |
| MME | Morphine Milligram Equivalent |
| D/S | Days Supply Limit |
| QL | Quantity Limit |
| AL | Age Limit |
| Generic Addition | A generic drug that recently became available in the marketplace |
| Generic Downtier | This generic drug will be covered at the appropriate preferred drug level of cost-sharing. |
| Generic Uptier | This generic drug will be covered at the appropriate non-preferred drug level of cost-sharing. |
| Authorized Generic Addition | An authorized generic drug that recently became available in the marketplace |
| Authorized Generic Uptier | Authorized generics are brand drugs that are marketed without the brand name on its label. An authorized generic may be marketed by the brand name drug company, or another company with the brand company's permission. Unlike a standard generic drug, the authorized generic is not approved by the Food and Drug Administration (FDA) abbreviated new drug application process (ANDA). This authorized generic drug will be covered at a higher level of cost-sharing similar to other brand name drugs. |
| Brand Downtier | These brand drugs were added to the formulary as of the date indicated and are covered at the appropriate preferred brand formulary level of cost-sharing. |
| Brand Uptier | These brand drugs will be covered at the appropriate non-preferred drug level of cost-sharing. |
| Brand Addition | Coverage was added to this drug. |
| Brand/Authorized Generic/ Generic Deletion | Coverage was removed from this drug. Formulary alternatives are available. |

www.ibx.com

Independence Blue Cross offers products through its subsidiaries Independence Hospital Indemnity Plan, Keystone Health Plan East and QCC Insurance Company, and with Highmark Blue Shield — independent licensees of the Blue Cross and Blue Shield Association.